Despite the relatively modest incidence of CCR7 effects on the progression of prostate cancer, it was noted in vitro that siRNA against CCR7, in PC-3 prostate adenocarcinoma cells, not only silenced CCR7 but also inhibited VEGF and MMP-9 protein expression [103]. The gene discussed is CCR7; the disease is prostate carcinoma.